Sort
21,281 grants matching “influenza”
Influenza and Emerging Infectious Diseases
$2,420,158Richard Davey · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Influenza Viral Pathogenesis
$2,419,893Jeffery Taubenberger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Biology and structure of pMHC receptors functioning as mechanosensors in the [alpha][beta] T-cell lineage
$2,418,542Ellis L Reinherz · Dana-Farber Cancer Inst · P01 · FY2023 · AI
Tissue Regulation of T Cell Function
$2,418,260Minsoo Kim · University Of Rochester · P01 · FY2022 · AI
NN/LM Region 6 RML and NN/LM Evaluation Office (NEO)
$2,417,207Tania P Bardyn · University Of Washington · UG4 · FY2019 · LM
Tissue Regulation of T Cell Function
$2,416,175Minsoo Kim · University Of Rochester · P01 · FY2023 · AI
Biology and structure of pMHC receptors functioning as mechanosensors in the [alpha][beta] T-cell lineage
$2,414,693Ellis L Reinherz · Dana-Farber Cancer Inst · P01 · FY2024 · AI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)
$2,413,871Richard Webby · St. Jude Children'S Research Hospital · N01 · FY2018 · AI
Influenza and Emerging Infectious Diseases
$2,412,678Richard Davey · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
$2,408,617Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2023 · AG
Immunological responses to pan-CoV vaccines
$2,408,043Yoshihiro Kawaoka · University Of Wisconsin-Madison · P01 · FY2021 · AI
Center for Biomedical Research Excellence in Pathogen-Host Interactions
$2,403,396Stephen B Pruett · Mississippi State University · P20 · FY2013 · GM
Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center
$2,402,774Richard G Wunderink · Northwestern University At Chicago · U19 · FY2024 · AI
Aging and Immunity to Infections
$2,402,413Laura Haynes · Trudeau Institute, Inc. · P01 · FY2009 · AG
Innovative Influenza Therapeutic and Prophylactic for Biodefense Applications
$2,401,735Jane Ryan · Biota Scientific Management · U01 · FY2006 · AI
Outpatient VE for seasonal flu, pandemic flu and RSV in a large, diverse network
$2,400,000Richard K Zimmerman · University Of Pittsburgh At Pittsburgh · U01 · FY2020 · IP
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE
$2,400,000Andrew Pekosz · Johns Hopkins University · N01 · FY2021 · AI
MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF SPANISH FLU
$2,397,637Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · P01 · FY2008 · AI
THE VIRAL BIOINFORMATICS RESOURCE CENTER
$2,396,552Aimee Walden · Northrop Grumman Systems · N01 · FY2015 · AI
Anti-viral immune responses in lymph node
$2,393,299Ulrich H Von Andrian · Harvard Medical School · P01 · FY2011 · AI
Phenotypic diversity in viral evolution
$2,392,928Tijana Ivanovic · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF SPANISH FLU
$2,392,160Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · P01 · FY2006 · AI
Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment
$2,391,540Alessandro Sette · La Jolla Institute For Immunology · U19 · FY2024 · AI
Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment
$2,391,540Alessandro Sette · La Jolla Institute For Immunology · U19 · FY2022 · AI
Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment
$2,391,540Alessandro Sette · La Jolla Institute For Immunology · U19 · FY2023 · AI